Abstracts tagged "outcomes and international"

Abstract Number: 2650 • 2019 ACR/ARP Annual Meeting
Predictors of Relapse in Giant Cell Arteritis: Data from an International Collaboration
Laure Delaval ¹, Raphael Porcher ², Kenneth Warrington ³, Francesco Muratore ⁴, Cynthia Crowson ⁵, Daniel Blockmans ⁶, Christian Agard ⁷, Alexis Régent ⁸, Maxime Samson ⁹, Loic Guillevin ⁸, Carlo Salvarani ¹⁰ and Benjamin Terrier⁸, ¹Department of Internal Medicine, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Paris, France, Paris, France, ²Hotel Dieu Hospital, Paris, France, ³Mayo Clinic Rochester, Rochester, MN, ⁴Division of Rheumatology, Azienda Unita’ Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁵Mayo Clinic Rochester, Rochester, ⁶Department of General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium, ⁷CHU Nantes, Nantes, France, ⁸National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ⁹Service de Médecine Interne et Immunologie Clinique, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon ; Université Bourgogne-Franche Comté, INSERM, EFS BFC, UMR1098, F-21000 Dijon, Dijon, France, ¹⁰Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
Background/Purpose: Roughly half of giant-cell arteritis (GCA) patients taking only glucocorticoids (GCs) relapse. The relapse rate seems to reflect, in part, the duration of GC intake, more…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].